Department of Surgery, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
Harvard Medical School, Boston, MA, USA.
Curr Diab Rep. 2019 Nov 14;19(11):125. doi: 10.1007/s11892-019-1236-0.
Bariatric surgery is a durable and long-term solution to treat both obesity and its associated comorbidities, specifically type 2 diabetes mellitus (T2DM). Many studies have demonstrated the benefits of bariatric surgery on T2DM, but weight recidivism along with recurrence of comorbidities can be seen following these procedures. Patient compliance post-bariatric surgery is linked to weight loss outcomes and comorbidity improvement/resolution. The role of compliance with respect to T2DM medication in bariatric patients specifically has not recently been examined. This article seeks to review the role of bariatric surgery on short- and long-term resolution of T2DM, recurrence, and compliance with T2DM medication following bariatric surgery.
Seven randomized control trials have examined metabolic surgery versus medical therapy in glycemic control in patients meeting criteria for severe obesity. Six out of seven studies demonstrate a significant advantage in the surgical arms with regards to glycemic control, as well as secondary endpoints such as weight loss, serum lipid levels, blood pressure, renal function, and other parameters. While patient compliance with lifestyle modifications post-bariatric surgery is linked to weight loss outcomes, there are no studies to date that directly evaluate the role of lifestyle modifications and T2DM medication adherence in the management of T2DM post-bariatric surgery. Bariatric surgery is an effective treatment option to achieve long-term weight loss and resolution of obesity-related medical comorbidities, specifically T2DM. Patient compliance to lifestyle modifications post-bariatric surgery is linked to weight loss outcomes and comorbidity resolution. The role of diabetic care compliance in bariatric patient outcomes, however, is poorly understood. Further studies are needed to elucidate the predictors and associated risk factors for non-compliance in this patient population.
减重手术是治疗肥胖及其相关合并症(尤其是 2 型糖尿病[T2DM])的一种持久且长期的解决方案。许多研究已经证明了减重手术对 T2DM 的益处,但在这些手术后,体重反弹和合并症复发是可以看到的。减重手术后患者的依从性与体重减轻的结果和合并症的改善/解决有关。术后患者对 T2DM 药物的依从性与减重患者的 T2DM 改善之间的关系尚未得到近期的研究检验。本文旨在回顾减重手术对 T2DM 的短期和长期缓解、复发以及减重手术后 T2DM 药物依从性的作用。
有七项随机对照试验研究了代谢手术与符合严重肥胖标准的患者的药物治疗在血糖控制方面的效果。七项研究中有六项表明手术组在血糖控制方面具有显著优势,以及体重减轻、血清脂质水平、血压、肾功能和其他参数等次要终点方面也具有显著优势。虽然减重手术后患者对生活方式改变的依从性与体重减轻的结果有关,但目前还没有研究直接评估生活方式改变和 T2DM 药物依从性在减重手术后 T2DM 管理中的作用。减重手术是一种有效的治疗选择,可以实现长期的体重减轻和肥胖相关医疗合并症(特别是 T2DM)的缓解。减重手术后患者对生活方式改变的依从性与体重减轻的结果和合并症的解决有关。然而,患者对减重治疗的依从性在很大程度上是未知的。需要进一步的研究来阐明该患者群体中不依从的预测因素和相关风险因素。